# FinalDose

Source: https://onco.cc/companies/finaldose/  
OnCo record `finaldose` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Y Combinator Spring 2026 start-up building a programmable DNA-targeting drug: a molecule that recognises a cancer-specific DNA sequence inside a cell and triggers a kill switch only there.

## Summary

Founded by three Oxford PhDs (Jeff Liu, Li-Yao Huang, Steven Lin). The pitch: swap the guide sequence and the same drug becomes a new drug, unlocking 'undruggable' drivers such as MYC, TP53, and APC at the DNA level and, the company claims, 80% of cancers that protein-targeted drugs cannot reach. Preclinical and pre-revenue, with no published data or trials by September 2026. Listed here as the clearest example of the sequence-programmable therapeutic concept.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: frontier; early-stage; yc
- HQ: San Francisco, CA
- Type: biotech
- Website: https://www.finaldose.ai/

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/finaldose
- Company site: https://www.finaldose.ai/

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Programmable DNA-targeting therapeutics](https://onco.cc/technologies/programmable-dna-targeting-therapeutics/)
- targets: [KRAS](https://onco.cc/targets/kras/), [TP53](https://onco.cc/targets/tp53/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)
- bottlenecks: [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)

---
JSON: https://onco.cc/api/v1/entities/finaldose.json